The trial is testing the scaffold’s ability to treat spinal cord injuries. According to the changes submitted to the FDA, InVivo wants to increase resources to the trial that were previously allocated for its hydrogel drug delivery platform.
More Articles on Devices:
Global Minimally Invasive Surgery Market to Reach $50.6B by 2019
Globus Medical Receives Spinal Fixation Patent
Alphatec Holdings Names Mike Plunkett as COO
